Modifiable Risk Factors for Cognitive Dysfunction in Patients With Coronary Heart Disease
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Coronary Heart Disease, Cognitive Impairment, Mild. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Association Between Modifiable Risk Factors and Cognitive Function in Patients With Coronary Heart Disease
Overview
This prospective observational study aims to investigate the association between risk factors and cognitive function in patients with coronary heart disease (CHD), and to explore the underlying mechanisms involving metabolic parameters and multimodal imaging features. A total of 2,352 participants will be enrolled from Beijing Anzhen Hospital, Capital Medical University, China. Eligible participants are adults (≥18 years) with confirmed CHD who undergo systematic neuropsychological assessment during hospitalization. Comprehensive assessments include cognitive function tests (MMSE, MoCA, BCAT, AD8), metabolic evaluations (fasting glucose, insulin, HbA1c, ceramides), coronary computed tomography angiography (CCTA), cardiac magnetic resonance (CMR), sleep respiratory monitoring, and frailty and psychological assessments.The primary outcome is cognitive impairment. The study will identify potential risk factors and provide insights into early identification and personalized intervention strategies for cognitive decline in CHD patients.This study is led by the National Clinical Research Center for Cardiovascular Diseases and invited to be carried out by several Chinese centers including Beijing Anzhen Hospital.
Primary outcome measures
- Cognitive impairment [Time frame: 2026-2031]
Eligibility criteria
Inclusion criteria
- Age ≥ 18 years
- Diagnosis of coronary heart disease (meeting at least one of the following):
- Coronary angiography or coronary CTA showing ≥50% stenosis in ≥1 major coronary artery;
- Established diagnosis of coronary heart disease with prior medical, interventional, or surgical treatment;
- Objective evidence of myocardial ischemia or typical clinical symptoms
- Completion of standardized neuropsychological assessment during hospitalization
- Completion of metabolic marker evaluation (fasting glucose, insulin, HbA1c, etc.) and agreement to undergo relevant imaging and functional assessments
- Provision of signed written informed consent
Exclusion criteria
- Previously diagnosed dementia.
- History of stroke, cerebral hemorrhage, or other central nervous system diseases known to cause cognitive impairment.
- Severe psychiatric disorders (e.g., schizophrenia, bipolar disorder).
- Pregnancy or breastfeeding.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- Beijing Anzhen Hospital — Beijing
Identifiers
NCT: NCT07657624 · Beijing Anzhen